RE:Malibu’s take Here's my take on this. BLO and BTH (Breathtec Biomedical) are linked with a similar basis of operation, namely a breath sample is used to determine level of cannabis use for one while a breath sample is used to detect diseases.
It could very well be that ownership is freeing up some cash to invest in BTH because of the parallel development for different purposes, and perhaps BTH has made significant progress since January 2018. Recency of use is not a necessary criteria for a disease detector, therefore a parameter which doesn't impede its development meaning it could come to market first. If it does, then it would only be excellent news for BLO.
https://ceo.ca/@nasdaq/breathtec-biomedical-provides-development-update-on
I'm taking a peek at BTH as it is only $0.13 and maybe, just maybe one might be a winner on 2 fronts.
DYODD and GLTA